Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 7/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.44 |
| ▸ | PDE1A | P54750 | 3/20 | 0.43 |
| ▸ | PDE1B | Q01064 | 3/20 | 0.43 |
| ▸ | PDE1C | Q14123 | 3/20 | 0.43 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.43 |
| ▸ | RAF1 | P04049 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20177018 | 0.88 | ALDH1A1 (0.55) | PDE1APDE1BPDE1CUCHL1 | |
| SCHEMBL4789449 | 0.80 | PDE1B (0.46) | NPBWR1MCHR1PDE1BUCHL1 | |
| SCHEMBL21796811 | 0.78 | NPBWR1 (0.46) | NPBWR1MCHR1PDE1APDE1BPDE1C | |
| SCHEMBL20177021 | 0.77 | PTGDR2 (0.43) | NPBWR1MCHR1PDE1APDE1BPDE1C | |
| SCHEMBL14809708 | 0.76 | NPBWR1 (0.51) | NPBWR1MCHR1UCHL1 | |
| SCHEMBL20746001 | 0.76 | NPBWR1 (0.51) | NPBWR1MCHR1UCHL1 | |
| SCHEMBL30051137 | 0.76 | NPBWR1 (0.46) | NPBWR1MCHR1UCHL1 | |
| SCHEMBL21384201 | 0.76 | NPBWR1 (0.45) | NPBWR1MCHR1PDE1APDE1BPDE1C | |
| SCHEMBL29049972 | 0.75 | PTPN1 (0.60) | NPBWR1MCHR1UCHL1 | |
| SCHEMBL21796474 | 0.75 | NPBWR1 (0.44) | NPBWR1MCHR1PDE1APDE1BPDE1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190352276-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | JOINT STOCK COMPANY "BIOCAD" (RU) | 2019-11-21 | — | — | US | disclosed |
| WO-2018092047-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | JOINT STOCK COMPANY "BIOCAD" (RU) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190352276-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, ABL1, CNKSR1 | NPBWR1 396/4885MCHR1 995/4885PDE1A 2289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.